Is Steel Dynamics (STLD) Outperforming Other Basic Materials Stocks This Year?
Nektar Therapeutics NKTR was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 29% in the past one-month time frame.
The stock gained after the company reported preliminary data from the ongoing PIVOT phase I/II study.
The company has seen five positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Nektar Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Nektar Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Nektar Therapeutics Price
Nektar Therapeutics Price | Nektar Therapeutics Quote
A better-ranked stock in the Medical - Drugs industry is ChemoCentryx, Inc. CCXI, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NKTR going up? Or down? Predict to see what others think: Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ChemoCentryx, Inc. (CCXI) : Free Stock Analysis Report
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research